Zometa improves survival in Phase III trial in multiple myeloma
This article was originally published in Scrip
Novartis's bisphosphonate Zometa (zoledronic acid) has become the first drug of its class to improve overall survival in multiple myeloma (MM) in combination with standard treatment in a Phase III trial, lending further credence to the belief that it has an anticancer effect in addition to its beneficial effects on bone.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.